HIF1A and nonpapillary renal cell carcinoma: Small molecule inhibitors of HIF-2α are under clinical development with promising efficacy in patients with advanced ccRCC; however, ccRCC tumors express both HIF-1α and -2α, and HIF-1α regulates independent and overlapping target genes with HIF-2α.